Solara Active Pharma Sciences Ltd. (IN:SOLARA)
:SOLARA
Want to see IN:SOLARA full AI Analyst Report?
SOLARA Stock Chart & Stats
₹582.80
-₹9.20(-1.31%)
At close: 4:00 PM EST
₹582.80
-₹9.20(-1.31%)
Day’s Range― - ―
52-Week Range₹422.85 - ₹734.20
Previous CloseN/A
Volume86.95K
Average Volume (3M)37.94K
Market Cap
₹28.00B
Enterprise Value₹32.02B
Total Cash (Recent Filing)₹169.30M
Total Debt (Recent Filing)₹6.46B
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.59
Shares Outstanding48,171,562
10 Day Avg. Volume26,889
30 Day Avg. Volume37,944
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.50
Price to Sales (P/S)1.37
P/FCF Ratio211.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.4
Revenue Forecast (FY)₹17.95B
Bulls Say, Bears Say
Bulls Say
API & CDMO Business ModelSolara's core focus on API manufacturing and contract development/manufacturing serves regulated and semi-regulated markets and is export-driven. That business mix creates recurring supply relationships, customer qualification barriers, and diversified revenue streams, supporting durable demand and long-term contract opportunities.
Revenue Recovery And Operating ProfitabilityA return to revenue growth (+13.5% in FY2026) alongside positive operating profit across FY2025–FY2026 indicates operational stabilization. Sustained top-line momentum with operating-level profitability suggests improving cost control and scale economics that, if maintained, can support consistent cash generation and reinvestment for growth.
Improved LeverageThe material reduction in leverage to roughly 0.55x improves financial flexibility and lowers interest burden. A healthier capital structure enhances the firm's ability to fund regulatory compliance, capital expenditures, and working capital needs without excessive refinancing risk, increasing resilience through industry cycles.
Bears Say
Weak Cash GenerationCash generation deteriorated sharply in FY2026, with OCF at 617m and free cash flow plunging ~80% to 88.8m. Persistent volatility in cash conversion limits internal funding for capex, R&D and working capital, increases dependence on external financing, and raises execution risk across multi-year API qualification and supply cycles.
Gross Margin VolatilityA decline in gross margin from about 51% to 27% within a year signals significant pricing, mix, or cost-pressure exposure. Such large swings undermine margin predictability, hurt long-run profitability planning for capital-intensive API production, and increase vulnerability to competitive pricing or raw-material shocks.
Net Loss And Weak ReturnsDespite operating-profit recovery, Solara reported a small net loss and negative ROE in FY2026, indicating financing, tax, or one-off items eroding bottom-line results. Failure to convert operating gains into net profitability hampers shareholder returns and constrains the company's ability to self-fund strategic investments over multiple quarters.
Solara Active Pharma Sciences Ltd. News
SOLARA FAQ
What was Solara Active Pharma Sciences Ltd.’s price range in the past 12 months?
Solara Active Pharma Sciences Ltd. lowest stock price was ₹422.85 and its highest was ₹734.20 in the past 12 months.
What is Solara Active Pharma Sciences Ltd.’s market cap?
Solara Active Pharma Sciences Ltd.’s market cap is ₹28.00B.
When is Solara Active Pharma Sciences Ltd.’s upcoming earnings report date?
Solara Active Pharma Sciences Ltd.’s upcoming earnings report date is Jul 30, 2026 which is in 46 days.
How were Solara Active Pharma Sciences Ltd.’s earnings last quarter?
Solara Active Pharma Sciences Ltd. released its earnings results on May 15, 2026. The company reported ₹2.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.2.
Is Solara Active Pharma Sciences Ltd. overvalued?
According to Wall Street analysts Solara Active Pharma Sciences Ltd.’s price is currently Overvalued.
Does Solara Active Pharma Sciences Ltd. pay dividends?
Solara Active Pharma Sciences Ltd. pays a Notavailable dividend of ₹3 which represents an annual dividend yield of N/A. See more information on Solara Active Pharma Sciences Ltd. dividends here
What is Solara Active Pharma Sciences Ltd.’s EPS estimate?
Solara Active Pharma Sciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solara Active Pharma Sciences Ltd. have?
Solara Active Pharma Sciences Ltd. has 48,171,562 shares outstanding.
What happened to Solara Active Pharma Sciences Ltd.’s price movement after its last earnings report?
Solara Active Pharma Sciences Ltd. reported an EPS of ₹2.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 14.324%.
Which hedge fund is a major shareholder of Solara Active Pharma Sciences Ltd.?
Currently, no hedge funds are holding shares in IN:SOLARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solara Active Pharma Sciences Ltd.
Solara Active Pharma Sciences Limited is an Indian-based pharmaceutical company primarily involved in the comprehensive development, production, and global trade of active pharmaceutical ingredients (APIs). Their activities span the manufacturing, processing, sale, import, and export of these essential drug components. The company's extensive product range includes APIs designed for a wide spectrum of therapeutic applications, such as anesthetics, antibiotics, antivirals, cardiovascular agents, central nervous system treatments, anti-inflammatory drugs, and treatments for metabolic disorders like type-II diabetes, among numerous other specialized categories. Beyond its core product offerings, Solara also delivers specialized contract research and manufacturing services (CRAMS) for APIs. These services encompass custom development and manufacturing, analytical support, impurity synthesis, and comprehensive regulatory assistance. The company maintains a significant international presence, exporting its products and conducting operations across diverse global regions, including the Asia Pacific, Europe, North America, and South America. Headquartered in Chennai, India, Solara Active Pharma Sciences Limited was established in 2017. Initially known as SSL Pharma Sciences Limited, the company adopted its current name in March of the same year.
Technical Analysis
Granules India Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Strides Pharma Science Ltd
―
Unichem Laboratories Limited
―